We’re proud to partner with Genentech by adding Hemlibra to our list of innovative therapies,” says Lisa Sackuvich, owner and president of ARJ Infusion Services. “It further demonstrates our commitment in providing the best care to patients.
KANSAS CITY, Miss. (PRWEB) December 01, 2017
ARJ Infusion Services, a leader in home infusion therapy, has been selected by Genentech to provide specialty pharmacy services for Hemlibra, a new limited-distribution drug approved earlier this month by U.S. Food and Drug Administration.
Hemlibra (emicizumab-kxwh) is the only prescription medication that can be self-administered subcutaneously to people with hemophilia A who have developed factor VIII inhibitors. As a prophylactic treatment, the highly anticipated drug has been shown to prevent or significantly reduce the frequency of bleeding episodes in children and adults who receive weekly injections.
“We’re proud to partner with Genentech by adding Hemlibra to our list of innovative therapies,” says Lisa Sackuvich, owner and president of ARJ Infusion Services. “It further demonstrates our commitment in providing the best care to patients.”
For nearly 20 years, ARJ has been a nationally recognized leader in delivering specialty pharmacy and nursing services to people with bleeding disorders and other complex genetic conditions. ARJ’s certified pharmacists and nurses specialize in customized infusion therapy, in-home nursing care, and on-site clinical treatments for adult and pediatric patients in all 50 states.
ARJ is accepting new patient referrals. Call 866-451-8804 or visit arjinfusion.com/hemlibra to download a patient referral form.
Learn more about Genentech’s Hemlibra product.
About ARJ Infusion Services
ARJ Infusion Services is a leader in specialty pharmacy and high-tech nursing services. We provide infusion therapies to children and adults with chronic and rare conditions. Our expertise includes bleeding and neurological disorders, immune deficiencies, and gastrointestinal and rheumatic conditions.
Hemophilia A is a rare genetic bleeding disorder caused by a missing or defective blood-clotting protein called factor VIII. The absence of factor VIII can lead to prolonged bleeding episodes and result in serious joint damage.